Genenta Science S.p.A. (GNTA) Stock Ticker
Market factors today
Unlock the full GNTA picture
About Genenta Science S.p.A.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
GNTA stock facts
| Ticker symbol | GNTA |
| Exchange | NASDAQ Capital Market |
| Sector | Industrials |
| Industry | Aerospace & Defense |
| Market cap | $13.2M |
| CEO | Pierluigi Paracchi |
| Employees | 9 |
| Headquarters | Milan, MI, IT |
| IPO date | 2021-12-15 |
| Website | www.genenta.com |
What you can see for GNTA on Tickr
Live GNTA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GNTA report.
Rankings
FAQ
What is the ticker symbol for Genenta Science S.p.A.?
The ticker symbol for Genenta Science S.p.A. is GNTA, listed on the NASDAQ Capital Market.
What is GNTA?
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an…